Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Multiple myeloma is a cancer that occurs when a type of white blood cell grows out of control, causing low blood counts, bone and calcium problems, frequent infections and kidney damage. According to ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...

This is a great question. So I personally think that CAR T-cell therapies, they do have a meaningful positive impact on quality of life for many myeloma patients, particularly after recovery from the ...

But we do have all these great treatments, and we're hoping that the overall survival of those patients will keep getting longer and longer, and maybe one day myeloma could be potentially cured. I ...

After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.

At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...